Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors

1 Aug 2018

Abstract excerpt

The discovery of molecular subtypes of non-small cell lung cancer (NSCLC) with oncogenic driver mutations and translocations/rearrangements has led to successful development of targeted therapies and improvement in outcomes of advanced lung cancer patients.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30327756
DOI: 10.21037/tcr.2018.08.11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsPMID 30327756Read ↗

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.Semantic proximity Read ↗

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

ALK and ROS1 as a joint target for the treatment of lung cancer: a review.Semantic proximity Read ↗

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Semantic proximity Read ↗

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to CrizotinibSemantic proximity Read ↗

Importance of ROS1 fene fusions in non-small cell lung cancerSemantic proximity Read ↗

Progress of non-small-cell lung cancer with ROS1 rearrangementSemantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.